Due to the diversity of its histone and non-histone substrates such as tumor suppressors, oncogenes, and steroid receptors [23,34,35,36,37,38] (Table 1), it is not surprising that deregulation of PRMT1 arginine methyltransferase activity may contribute to BC initiation and progression [39,40]. The gene discussed is PRMT1; the disease is breast cancer.